Peracetylated EGCG |
Jurkat T |
Leukemic |
Being more stable than free EGCG at neutral pH and showing greater efficacy in proteasome inhibition and cell death induction. |
[87] |
KYSE150, HCT116 |
Esophageal and colon |
Increasing the biological potency in vitro and the bioavailability of EGCG in esophageal or colon cancer cells. |
[88] |
|
Colon |
Showing stronger prevention potency to DSS-induced colitis than free EGCG. |
[89] |
CD34+ |
Skin |
Preventing skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors |
[90] |
MDA-MB-231 |
Breast |
Increasing the bioavailability, stability, and proteasome inhibition and anticancer activities of EGCG in human breast cancer cells and tumors. |
[91] |
CWR22R |
Prostate |
Being more stable, increasing the therapeutic anticancer effects in androgen-independent prostate cancer |
[92] |
|
Endometrium |
Inhibiting the growth, development and angiogenesis of experimental endometriosis in mice, with improved efficacy, bioavailability, anti-oxidation and anti-angiogenesis capacities. |
[93] |
Inhibiting tumor angiogenesis through downregulation of VEGFA and HIF1α in tumor cell and chemokine(C-X-C motif) ligand 12 in host stroma. |
[94] |
Synthetic EGCG analogs 4 and 6 (Figure 2) |
MDA-MB-231 |
Breast |
Activating AMPK, with inhibition of cell proliferation, up-regulation of the cyclin-dependent kinase inhibitor p21, down-regulation of mTOR pathway, and suppression of stem cell population in human breast cancer cells. |
[95] |